Author:
Hobson Claire Amaris,Cointe Aurélie,Jacquier Hervé,Choudhury Alaksh,Magnan Mélanie,Courroux Céline,Tenaillon Olivier,Bonacorsi Stéphane,Birgy André
Funder
Fondation ARC pour la Recherche sur le Cancer
Association pour la Recherche Therapeutique Anti-Cancereuse
Subject
Infectious Diseases,Microbiology (medical),General Medicine
Reference15 articles.
1. No time to wait: securing the future from drug-resistant infections. Report to the secretary-general of the United Nations,2019
2. In vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant gram-negative bacilli from North America and Europe, including carbapenem-nonsusceptible isolates (SIDERO-WT-2014 Study);Hackel;Antimicrob Agents Chemother,2017
3. KPC beta-lactamases are permissive to insertions and deletions conferring substrate spectrum modifications and resistance to ceftazidime-avibactam;Hobson;Antimicrob Agents Chemother,2020
4. Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae infections;Shields;Antimicrob Agents Chemother,2018
5. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial;Wunderink;Lancet Infect Dis,2021
Cited by
69 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献